Biologix is a Dubai-based firm that represents international pharma companies by bringing innovative drugs to market in the Middle East / North Africa (MENA) region. Its GM, Zeina Sfeir Lahoud, discusses the company’s presence in over 17 countries, their 25 years of experience in Saudi Arabia, and the dynamics shaping the largest market in the region, including the fast regulatory approval process in place. With value-based healthcare an increasingly hot topic, she explains how Biologix has moved to sign the first risk-sharing agreement with Saudi Arabia for a spinal muscular atrophy product; the first in the MENA region.
STAY UP TO DATE NEWS & EVENTS
Related EVENTS & NEWS
Market Access Team Cycle Meeting 2022
Biologix at the 34th Annual Conference of the Saudi Heart Association 2023
Biologix has participated in the 34th Annual Conference of the Saudi Heart Association (SHA) held from October 12 to 14, 2023 as a golden sponsor.
Biologix's Participation at DUPHAT 2024
As part of our commitment to bring innovative products and solutions for difficult-to-treat diseases in the MENA region, Biologix ...
